keyword
https://read.qxmd.com/read/38429124/the-role-of-neoadjuvant-chemotherapy-for-patients-with-variant-histology-muscle-invasive-bladder-cancer-undergoing-robotic-cystectomy-data-from-the-international-robotic-cystectomy-consortium
#21
JOURNAL ARTICLE
Ian Cooke, Nassib Abou Heidar, Abdul Wasay Mahmood, Ali Ahmad, Zhe Jing, Michael Stöckle, Andrew A Wagner, Morgan Roupret, Eric Kim, Nikhil Vasdev, Derya Balbay, Koon Ho Rha, Ahmed Aboumohamed, Prokar Dasgupta, Thomas J Maatman, Lee Richstone, Peter Wiklund, Franco Gaboardi, Qiang Li, Ahmed A Hussein, Khurshid Guru
OBJECTIVE: To assess the role of neoadjuvant chemotherapy (NAC) before robot-assisted radical cystectomy (RARC) for patients with variant histology (VH) muscle-invasive bladder cancer (MIBC). METHODS: Retrospective review of 988 patients who underwent RARC (2004-2023) for MIBC. Primary outcomes included the utilization of NAC among this cohort of patients, frequency of downstaging, and discordance between preoperative and final pathology in terms of the presence of VH...
February 29, 2024: Urologic Oncology
https://read.qxmd.com/read/38428891/brain-metastasis-in-a-patient-with-brca2-mutated-treatment-related-neuroendocrine-prostate-carcinoma-and-long-term-response-to-radiotherapy-and-olaparib-a-case-report-and-literature-review
#22
JOURNAL ARTICLE
Rio Uehara, Daisuke Obinata, Sho Hashimoto, Ken Nakahara, Hideaki Uchida, Tsuyoshi Yoshizawa, Junichi Mochida, Kenya Yamaguchi, Masakuni Sakaguchi, Yoshinari Ozawa, Fumi Mori, Katsuhiro Miura, Toshiyuki Ishige, Shinobu Masuda, Tomohiro Nakayama, Satoru Takahashi
BACKGROUND: A new subtype of prostate cancer called treatment-related neuroendocrine prostate carcinoma (t-NEPC) was added to the revised World Health Organization classification of prostate cancer in 2022. t-NEPC cases are increasing, and there is no established standard treatment. METHODS: A 49-year-old male patient was referred to our department for dysuria. A rectal examination and a prostate biopsy revealed stony hardness and prostate adenocarcinoma, respectively...
March 1, 2024: Medicine (Baltimore)
https://read.qxmd.com/read/38428534/analysis-of-pharmacokinetic-profile-and-ecotoxicological-character-of-cefepime-and-its-photodegradation-products
#23
JOURNAL ARTICLE
Joanna Żandarek, Paweł Żmudzki, Darija Obradović, Saša Lazović, Aleksandar Bogojević, Oliwia Koszła, Przemysław Sołek, Monika Maciąg, Anita Płazińska, Małgorzata Starek, Monika Dąbrowska
An important problem is the impact of photodegradation on product toxicity in biological tests, which may be complex and context-dependent. Previous studies have described the pharmacology of cefepime, but the toxicological effects of its photodegradation products remain largely unknown. Therefore, photodegradation studies were undertaken in conditions similar to those occurring in biological systems in silico, in vitro, in vivo and ecotoxicological experiments. The structures of four cefepime photodegradation products were determined by UPLC-MS/MS method...
February 28, 2024: Chemosphere
https://read.qxmd.com/read/38427957/18f-fdg-and-68ga-psma-pet-ct-in-paratesticular-mesothelioma
#24
JOURNAL ARTICLE
Forough Kalantari, Gregor Schweighofer-Zwink, Gundula Rendl, Christian Pirich, Mohsen Beheshti
A 66-year-old man with local prostate adenocarcinoma underwent radical prostatectomy (Gleason score 3 + 4 = 7, pT2c) in 2016. Four years later, he presented with a hydrocele and cystic atypical change in the left scrotum and soft tissue in the left groin. Final histopathology revealed spermatic cord mesothelioma and left hemangiosis carcinomatosa. A bone biopsy of the sacrum revealed infiltrates of a prostatic adenocarcinoma with small cell neuroendocrine differentiation. Dual-tracer PET/CT imaging using 18F-FDG and 68Ga-PSMA was able to identify local recurrence of scrotal mesothelioma and differentiate metastases of prostate cancer from malignant mesothelioma...
April 1, 2024: Clinical Nuclear Medicine
https://read.qxmd.com/read/38427749/comparison-of-molecular-analysis-results-determined-by-next-generation-sequencing-to-immunohistochemical-indicators-and-clinicopathological-parameters-in-prostate-adenocarcinomas
#25
JOURNAL ARTICLE
Merve Çırak Balta, İbrahim Halil Erdoğdu, Esin Oktay, Nil Çulhac
BACKGROUND: Prostate cancer is a common cancer in males, frequently leading to mortality. Multiple genetic factors play roles in prostate cancer pathogenesis. Demonstration of pathological pathways and customised treatment options have been possible with next-generation sequencing. AIM: In this study, we aimed to evaluate the relationships of the changes in the prostate cancer pathways genes with the pathological, immunohistochemical and the clinical parameters...
February 19, 2024: Indian Journal of Pathology & Microbiology
https://read.qxmd.com/read/38420334/an-elusive-prostate-tumour-metastatic-microcystic-cribriform-carcinoma-presenting-with-imaging-histologic-discordance
#26
Chun Khai Loh, Juanita Noeline Chui, Kevin Yinkit Zhuo, Ashan Canagasingham, Alexander Guminski, Warick Delprado, Thomas Eade, Matthew Winter
Microcystic adenocarcinoma is an uncommon histologic variant of prostate carcinoma. Despite its rarity, it has gained increasing recognition over the past decade for its diagnostic challenges and unclear prognostic significance. Herein, we describe a rare case of metastatic microcystic prostate adenocarcinoma, presenting with discordance between imaging and histologic findings. This report highlights the diagnostic and therapeutic challenges of this pathological entity and the importance of multidisciplinary collaboration in the management of intermediate-risk prostate cancer...
March 2024: Urology Case Reports
https://read.qxmd.com/read/38419802/effects-of-nuclear-interaction-corrections-and-trichrome-fragment-spectra-modelling-on-dose-and-linear-energy-transfer-distributions-in-carbon-ion-radiotherapy
#27
JOURNAL ARTICLE
Alessia Bazani, Jacob Brunner, Stefania Russo, Antonio Carlino, Daniel Simon Colomar, Walter Ikegami Andersson, Mario Ciocca, Markus Stock, Piero Fossati, Ester Orlandi, Lars Glimelius, Silvia Molinelli, Barbara Knäusl
BACKGROUND AND PURPOSE: Nuclear interaction correction (NIC) and trichrome fragment spectra modelling improve relative biological effectiveness-weighted dose (DRBE ) and dose-averaged linear energy transfer (LETd ) calculation for carbon ions. The effect of those novel approaches on the clinical dose and LET distributions was investigated. MATERIALS AND METHODS: The effect of the NIC and trichrome algorithm was assessed, creating single beam plans for a virtual water phantom with standard settings and NIC + trichrome corrections...
January 2024: Physics and Imaging in Radiation Oncology
https://read.qxmd.com/read/38413763/genomic-attributes-of-prostate-cancer-across-primary-and-metastatic-noncastrate-and-castrate-resistant-disease-states-a-next-generation-sequencing-study-of-183-patients
#28
JOURNAL ARTICLE
Surendra Dasari, Michael R McCarthy, Antonina A Wojcik, Beth A Pitel, Arpan Samaddar, Burak Tekin, Rumeal D Whaley, Aditya Raghunathan, Loren Herrera Hernandez, Rafael E Jimenez, Brad J Stish, R Houston Thompson, Bradley C Leibovich, Stephen A Boorjian, R Jeffrey Karnes, Daniel S Childs, J Fernando Quevedo, Eugene D Kwon, Lance C Pagliaro, Brian A Costello, Kevin C Halling, John C Cheville, Benjamin R Kipp, Sounak Gupta
Primary prostatic adenocarcinoma (pPC) undergoes genomic evolution secondary to therapy-related selection pressures as it transitions to metastatic noncastrate (mNC-PC) and castrate resistant (mCR-PC) disease. Next generation sequencing results were evaluated for pPC (n = 97), locally advanced disease (involving urinary bladder/rectum, n = 12), mNC-PC (n = 21), and mCR-PC (n = 54). We identified enrichment of TP53 alterations in high-grade pPC, TP53/RB1 alterations in HGNE disease, and AR alterations in metastatic and castrate resistant disease...
February 27, 2024: Prostate Cancer and Prostatic Diseases
https://read.qxmd.com/read/38412650/new-2-oxoindole-derivatives-as-multiple-pdgfr%C3%AE-%C3%A3-and-vegfr-2-tyrosine-kinase-inhibitors
#29
JOURNAL ARTICLE
Hend A A Ezelarab, Amer Ali Abd El-Hafeez, Taha F S Ali, Ahmed M Sayed, Heba A Hassan, Eman A M Beshr, Samar H Abbas
Two new series of N-aryl acetamides 6a-o and benzyloxy benzylidenes 9a-p based 2-oxoindole derivatives were designed as potent antiproliferative multiple kinase inhibitors. The results of one-dose NCI antiproliferative screening for compounds 6a-o and 9a-p elucidated that the most promising antiproliferative scaffolds were 6f and 9f, which underwent five-dose testing. Notably, the amido congener 6f was the most potent derivative towards pancreatic ductal adenocarcinoma MDA-PATC53 and PL45 cell lines (IC50  = 1...
February 22, 2024: Bioorganic Chemistry
https://read.qxmd.com/read/38409850/genomic-analysis-of-primary-epithelial-neoplasms-of-the-seminal-vesicle-identifies-a-subset-of-mucinous-cystic-tumours-driven-by-kras-mutations
#30
JOURNAL ARTICLE
Katrina Collins, Laurence A Galea, Forough Foroughi, Stephanie E Siegmund, William J Anderson, Sree Appu, Muhammad T Idrees, Thomas M Ulbright, Andres M Acosta
BACKGROUND: Carcinomas of the seminal vesicle are exceedingly rare, with a limited number of cases described in the literature. Reported cases span a relatively wide morphological spectrum, and their genomic features remain unexplored. DESIGN: In this study, we interrogated five primary epithelial neoplasms of the seminal vesicle using a targeted DNA sequencing platform (OncoPanel, 447 genes). RESULTS: The tumours included one adenocarcinoma with intestinal phenotype presenting after external beam radiation (for prostatic adenocarcinoma), one carcinoma with Müllerian-type clear cell phenotype, two mucinous tumours resembling low-grade mucinous neoplasms of the appendix (LAMN) and one mucinous cystadenoma...
February 26, 2024: Histopathology
https://read.qxmd.com/read/38406993/organometallic-ru-ii-rh-iii-and-re-i-complexes-of-sterane-based-bidentate-ligands-synthesis-solution-speciation-interaction-with-biomolecules-and-anticancer-activity
#31
JOURNAL ARTICLE
Tamás Pivarcsik, Márton A Kiss, Uroš Rapuš, Jakob Kljun, Gabriella Spengler, Éva Frank, Iztok Turel, Éva A Enyedy
In this study, we present the synthesis, characterization and in vitro cytotoxicity of six organometallic [Ru(II)(η6 - p -cymene)( N , N )Cl]Cl, [Rh(III)(η5 -C5 Me5 )( N , N )Cl]Cl and [Re(I)(CO)3 ( N , N )Cl] complexes, in which the ( N , N ) ligands are sterane-based 2,2'-bipyridine derivatives (4-Me-bpy-St-OH, 4-Ph-bpy-St-OH). The solution chemical behavior of the ligands and the complexes was explored by UV-visible spectrophotometry and 1 H NMR spectroscopy. The ligands and their Re(I) complexes are neutral at pH = 7...
February 26, 2024: Dalton Transactions: An International Journal of Inorganic Chemistry
https://read.qxmd.com/read/38405800/lineage-specific-canonical-and-non-canonical-activity-of-ezh2-in-advanced-prostate-cancer-subtypes
#32
Varadha Balaji Venkadakrishnan, Adam G Presser, Richa Singh, Matthew A Booker, Nicole A Traphagen, Kenny Weng, Nathaniel C Voss, Navin R Mahadevan, Kei Mizuno, Loredana Puca, Osasenaga Idahor, Sheng-Yu Ku, Martin K Bakht, Ashir A Borah, Zachary T Herbert, Michael Y Tolstorukov, David A Barbie, David S Rickman, Myles Brown, Himisha Beltran
Enhancer of zeste homolog 2 (EZH2) is a histone methyltransferase and emerging therapeutic target that is overexpressed in most castration resistant prostate cancers and implicated as a driver of disease progression and resistance to hormonal therapies. Here we define the lineage-specific action and differential activity of EZH2 in both prostate adenocarcinoma (PRAD) and neuroendocrine prostate cancer (NEPC) subtypes of advanced prostate cancer to better understand the role of EZH2 in modulating differentiation, lineage plasticity, and to identify mediators of response and resistance to EZH2 inhibitor therapy...
February 8, 2024: Research Square
https://read.qxmd.com/read/38401083/acidic-leucine-rich-nuclear-protein-phosphatase-32b-promotes-prostate-adenocarcinoma-cell-progression-by-regulating-apoptosis-and-epithelial-mesenchymal-transition
#33
JOURNAL ARTICLE
Min A, Lei Wang, Yonghao Xue, Chaoqi Wang
OBJECTIVE: This work aimed to investigate the expression of acidic leucine-rich nuclear protein phosphatase 32B (ANP32B) in prostate adenocarcinoma (PRAD) and evaluate the effect of ANP32B on the proliferation of prostate adenocarcinoma cells. METHODS: We evaluated the expression of ANP32B in PRAD tissues and cells compared to the controls obtained from The Cancer Genome Atlas (TCGA). siRNA targeting ANP32B was transfected into DU145 cells to knockdown the ANP32B expression and plasmids carrying ANP32B coding region were used to overexpress ANP32B in PC3 cells...
February 9, 2024: Alternative Therapies in Health and Medicine
https://read.qxmd.com/read/38397134/dardn-a-deep-learning-approach-for-ctcf-binding-sequence-classification-and-oncogenic-regulatory-feature-discovery
#34
JOURNAL ARTICLE
Hyun Jae Cho, Zhenjia Wang, Yidan Cong, Stefan Bekiranov, Aidong Zhang, Chongzhi Zang
Characterization of gene regulatory mechanisms in cancer is a key task in cancer genomics. CCCTC-binding factor (CTCF), a DNA binding protein, exhibits specific binding patterns in the genome of cancer cells and has a non-canonical function to facilitate oncogenic transcription programs by cooperating with transcription factors bound at flanking distal regions. Identification of DNA sequence features from a broad genomic region that distinguish cancer-specific CTCF binding sites from regular CTCF binding sites can help find oncogenic transcription factors in a cancer type...
January 23, 2024: Genes
https://read.qxmd.com/read/38396556/clinicopathologic-characterization-of-prostatic-cancer-in-dogs
#35
JOURNAL ARTICLE
Demitria M Vasilatis, Paramita M Ghosh
Clinicopathologic data in dogs with prostate cancer (PCa) may aid in the differentiation between tumor types and subsequent treatment decisions; however, these data are often unreported. Demographic, clinicopathologic, cytologic, histologic and survival data from dogs with primary prostatic adenocarcinoma (PRAD) ( n = 56) and primary prostatic transitional cell carcinoma (P-TCC) ( n = 74) were acquired from a tertiary veterinary teaching hospital from 1992 to 2022. Red blood cell distribution width (RDW) to albumin ratio (RAR) was evaluated for diagnostic utility in differentiating between PRAD and P-TCC...
February 10, 2024: Animals: An Open Access Journal From MDPI
https://read.qxmd.com/read/38396008/single-cell-transcriptomic-analysis-informs-the-lncrna-landscape-in-metastatic-castration-resistant-prostate-cancer
#36
JOURNAL ARTICLE
Debanjan Saha, Ha X Dang, Meng Zhang, David A Quigley, Felix Y Feng, Christopher A Maher
Metastatic castration-resistant prostate cancer (mCRPC) is a lethal form of prostate cancer. Although long-noncoding RNAs (lncRNAs) have been implicated in mCRPC, past studies have relied on bulk sequencing methods with low depth and lack of single-cell resolution. Hence, we performed a lncRNA-focused analysis of single-cell RNA-sequencing data (n = 14) from mCRPC biopsies followed by integration with bulk multi-omic datasets. This yielded 389 cell-enriched lncRNAs in prostate cancer cells and the tumor microenvironment (TME)...
February 23, 2024: NPJ Genomic Medicine
https://read.qxmd.com/read/38391963/subtype-transdifferentiation-in-human-cancer-the-power-of-tissue-plasticity-in-tumor-progression
#37
REVIEW
Monica Fedele, Laura Cerchia, Sabrina Battista
The classification of tumors into subtypes, characterized by phenotypes determined by specific differentiation pathways, aids diagnosis and directs therapy towards targeted approaches. However, with the advent and explosion of next-generation sequencing, cancer phenotypes are turning out to be far more heterogenous than initially thought, and the classification is continually being updated to include more subtypes. Tumors are indeed highly dynamic, and they can evolve and undergo various changes in their characteristics during disease progression...
February 17, 2024: Cells
https://read.qxmd.com/read/38391304/assessment-of-ki-67-expression-in-cases-of-prostatic-carcinoma-and-its-correlation-with-clinical-outcomes
#38
JOURNAL ARTICLE
Sumaira Siddiqui
BACKGROUND: Treatment decisions after diagnosis of clinically localized prostate cancer are difficult due to variability in tumor behavior. As there is a high prevalence of low-grade prostate cancer with an indolent course, we need improved markers of prostate cancer lethality in order to reduce the overtreatment. In the current study, we assessed Ki-67 expression in cases of prostate carcinoma and correlated its expression with clinical outcomes. METHODS: It was a single-center retrospective descriptive type of study...
February 14, 2024: Indian Journal of Pathology & Microbiology
https://read.qxmd.com/read/38385480/synthesis-in-silico-studies-and-in%C3%A2-vitro-biological-evaluation-of-newly-designed-5-amino-1-h-tetrazole-linked-5-fluorouracil-analog-as-a-potential-antigastric-cancer-agent
#39
JOURNAL ARTICLE
Javad Nowdehi, Elaheh Mosaddegh, Samad Khaksar, Masoud Torkzadeh-Mahani, Maria Beihaghi, Mohsen Yazdani
5-Fluorouracil (5FU) is a chemotherapy drug used to treat various cancers, such as colorectal, prostate, skin, pancreas, and stomach, as an ointment or solution. However, its consumption has several side effects. Therefore, a new derivative of fluorouracil containing 5-Amino-1H-tetrazole was designed and synthesized through multi-step synthesis to reduce urea excretion and toxicity. The effectiveness of the synthesized drug on the Adenocarcinoma gastric cell line (AGS) gastric cancer cell line was evaluated using the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) test, which showed that the new 5-fluorouracil (5FU) analog, with an IC50 of 15...
February 22, 2024: Journal of Biomolecular Structure & Dynamics
https://read.qxmd.com/read/38379333/molecular-complexity-of-intraductal-carcinoma-of-the-prostate
#40
REVIEW
Sha Zhu, Nanwei Xu, Hao Zeng
Intraductal carcinoma of the prostate (IDC-P) is an aggressive subtype of prostate cancer characterized by the growth of tumor cells within the prostate ducts. It is often found alongside invasive carcinoma and is associated with poor prognosis. Understanding the molecular mechanisms driving IDC-P is crucial for improved diagnosis, prognosis, and treatment strategies. This review summarizes the molecular characteristics of IDC-P and their prognostic indications, comparing them to conventional prostate acinar adenocarcinoma, to gain insights into its unique behavior and identify potential therapeutic targets...
January 2024: Cancer Medicine
keyword
keyword
101317
2
3
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.